Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 - - Total Revenue was $37.9 ...

Trump’s main effort, which he cited on August 3, centers on getting drugmakers to offer the same price in the US as they do in Europe and other peer countries, the so-called “Most Favored Nation” ...